The first-in-human study of BGB-45035 will assess its safety and pharmacokinetics in healthy participants and adults with autoimmune dermatological diseases.

ClinicalJune 19, 2026

Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy

Teva is conducting a trial to assess the safety and efficacy of TEV-53408 in adults with vitiligo over an 84-week period.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Tretinoin ANDA214590 by Alembic

The FDA has granted approval for Alembic's Abbreviated New Drug Application (ANDA) for Tretinoin.

RegulatoryJune 17, 2026

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.

ClinicalJune 17, 2026

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.

RegulatoryJune 16, 2026

FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen

Lilly's EBGLYSS® (lebrikizumab-lbkz) is now approved for a maintenance dose every eight weeks, requiring only six injections per year.

CompetitiveJune 13, 2026

Phase 3 Study of CU-20101 Shows Promise for Glabellar Lines Compared to Botox

A Phase 3 clinical study is underway to assess CU-20101's efficacy and safety against Botox for glabellar lines.

ClinicalJune 12, 2026

Trial Compares Silicone Barrier Spray to Zinc Oxide for Incontinence-Associated Dermatitis

A randomized controlled trial is evaluating the effectiveness of silicone barrier spray versus zinc oxide ointment for mild incontinence-associated dermatitis.

Upcoming catalysts(1)

Label Expansion

Incyte — Opzelura

Pediatric vitiligo label would deepen JAK inhibitor franchise in dermatology.

September 5, 2026 · Approved

Indications

Autoimmune Disease →

Autoimmune Diseases →

Vitiligo (pediatric) →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.